729. Deputy Conor Sheehan asked the Minister for Health if she plans to broaden the reimbursement criteria for GLP-1 medications, such as ozempic, under the drugs payment scheme or long-term illness scheme to include patients diagnosed with metabolic disorders, including polycystic metabolic syndrome and polycystic ovary syndrome, where insulin resistance is a core clinical symptom; her views on whether she intends to expand funding beyond restricting it exclusively to those with established Type 2 diabetes; and if she will make a statement on the matter. [47128/26]

Summary

729. Deputy Conor Sheehan asked the Minister for Health if she plans to broaden the reimbursement criteria for GLP-1 medications, such as ozempic, under the drugs payment scheme or long-term illness scheme to include patients diagnosed with metabolic disorders, including polycystic metabolic syndrome and polycystic ovary syndrome, where insulin resistance is a core clinical symptom; her views on whether she intends to expand funding beyond restricting it exclusively to those with established Type 2 diabetes; and if she will make a statement on the matter. [47128/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 23 June 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.